Compare SXC & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXC | IRWD |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | 848 | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 516.5M | 741.8M |
| IPO Year | 2011 | 2009 |
| Metric | SXC | IRWD |
|---|---|---|
| Price | $5.84 | $3.37 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 5 |
| Target Price | ★ $9.00 | $4.94 |
| AVG Volume (30 Days) | 2.0M | ★ 2.7M |
| Earning Date | 05-20-2026 | 05-26-2026 |
| Dividend Yield | ★ 8.25% | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | ★ $1,600,300,000.00 | $298,276,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | $4.39 |
| P/E Ratio | ★ N/A | $22.47 |
| Revenue Growth | ★ 10.30 | 8.88 |
| 52 Week Low | $5.52 | $0.55 |
| 52 Week High | $9.82 | $5.78 |
| Indicator | SXC | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 37.74 |
| Support Level | $5.52 | $3.08 |
| Resistance Level | $6.97 | $3.53 |
| Average True Range (ATR) | 0.30 | 0.28 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 32.31 | 44.50 |
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is mainly used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through two segments: Domestic Coke and Industrial Services. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal-producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.